Randomised Phase II study of combined Docetaxel and Nedaplatin versus Docetaxel alone chemotherapy in advanced or recurrent esophageal cancer

INTERVENTION: NDP(80mg/m2) and DOC(60mg/m2) combination chemotherapy DOC (70mg/m2) chemotherapy CONDITION: Advanced or recurrent esophageal cancer PRIMARY OUTCOME: Overall survival SECONDARY OUTCOME: overall survival, one year survival rate, progression free survival, objective response rate, adverse events INCLUSION CRITERIA: 1.recurreent esophageal cancer 2.the tumor has a measurable lesion for evaluation. 3.5FU/CDDP resistance 4.ECOG PS:0 to 2 5.Age from 20 to 80 years 6.Adequate organ function WBC:>3,000/ mm3 <12,000/mm3 Neutro:>1,500/mm3 Hb:>9.0 g/dl Plt:>100,000/mm3 T‐Bil:<1.5mg / dl AST(GOT),ALT(GPT):within 2.5 times the normal upper limits Ccr: 1.5mg/dl C.Cr:>50ml / min (Cockcroft‐ Gault) 7. Written informed consent